The estimated Net Worth of Sunil Agarwal is at least $3.67 Million dollars as of 13 June 2020. Sunil Agarwal owns over 2,300 units of MyoKardia stock worth over $517,293 and over the last 10 years he sold MYOK stock worth over $2,785,094. In addition, he makes $367,686 as Independent Director at MyoKardia.
Sunil has made over 16 trades of the MyoKardia stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 2,300 units of MYOK stock worth $517,293 on 13 June 2020.
The largest trade he's ever made was selling 17,020 units of MyoKardia stock on 19 August 2015 worth over $1,892,284. On average, Sunil trades about 691 units every 35 days since 2014. As of 13 June 2020 he still owns at least 2,300 units of MyoKardia stock.
You can see the complete history of Sunil Agarwal stock trades at the bottom of the page.
Dr. Sunil Agarwal M.D. serves as Independent Director of the Company. Since September 2018, Dr. Agarwal has served as chief development officer for Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicine for patients. Prior to that, Dr. Agarwal served as president of research and development at Juno Therapeutics, Inc., a biopharmaceutical company, from April 2017 to May 2018. Prior to Juno, Dr. Agarwal served as partner at Sofinnova Ventures from August 2016 to April 2017. Prior to Sofinnova, Dr. Agarwal served as the chief medical officer and senior vice president of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, from August 2014 to August 2016. Prior to Ultragenyx, Dr. Agarwal served in various leadership capacities at Genentech, Inc. (acquired by Roche Holdings, Inc.) for 11 years. Most recently, he held the position of senior vice president and global head of clinical development for OMNI (Ophthalmology, Metabolism, Neurosciences, Immunology and Infectious Diseases) from January 2013 to July 2014. Prior to that, Dr. Agarwal held the positions of senior vice president for Immunology and Infectious Diseases, and vice president for rheumatology from July 2009 to December 2012. He also held the position of vice president of enentech drug safety from January 2009 to July 2009. From September 2003 to January 2009, Dr. Agarwal held positions of increasing responsibility in Genentech’s Immunology clinical organization and was involved in the development oversight of multiple molecules including Raptiva, Rituxan, and Ocrelizumab. Dr. Agarwal currently serves on the board of directors of Calithera Biosciences, Inc. (NASDAQ: CALA), a biopharmaceutical company. Dr. Agarwal obtained his B.S. in neurobiology at Cornell University and then earned his M.D. from Tufts University School of Medicine.
As the Independent Director of MyoKardia, the total compensation of Sunil Agarwal at MyoKardia is $367,686. There are 7 executives at MyoKardia getting paid more, with Tassos Gianakakos having the highest compensation of $10,223,600.
Sunil Agarwal is 50, he's been the Independent Director of MyoKardia since 2016. There are 8 older and 3 younger executives at MyoKardia. The oldest executive at MyoKardia, Inc. is Mary Cranston, 72, who is the Independent Director.
Sunil's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN, CT, 06511.
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr und Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
MyoKardia executives and other stock owners filed with the SEC include: